Leukopenia
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
For CDA rs2072671 (A>C), AC and CC patients had a lower risk of neutropenia than AA patients (P=0.01, hazard ratio: 0.61, 95% confidence interval: 0.41-0.89).
|
30889042 |
2019 |
Leukopenia
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
However, patients with the variant CDA 79C allele would experience more grade ≥ 3 leucopenia (OR=2.933, 95% CI 1.357-6.605) and tended to have more severe neutropenia (OR=1.313, 95% CI 0.157-10.981).
|
25582275 |
2015 |
Leukopenia
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Our study suggests that CDA 79A>C mutation might be a potential risk factor of gemcitabine-induced neutropenia toxicity.
|
22546611 |
2012 |
Leukopenia
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Patients carrying the nonsynonymous CDA SNP 79A >C (CDA*2) had a 21% lower gemcitabine clearance as compared to wild-type patients (outcomes and complications.0.0009), but the risk for chemotherapy-associated neutropenia (61% vs. 32%, P = 0.07) and severe neutropenia (17% vs. 5%, P = 0.26) was not significantly higher.
|
21590444 |
2012 |
Leukopenia
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Carriers of the mutant adenosine triphosphate-dependent DNA helicase Q1 (RECQ1) C allele or the mutant cytidine deaminase (CDA) C allele were more likely to experience severe leukocytopenia (26% vs 10% [P = .03] and 28% vs 11% [P = .02], respectively) compared with wild-type genotype carriers.
|
22031394 |
2012 |
Leukopenia
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
CDA C111T, dCK C-1205T, dCK A9846G, and hCNT3 A25G, individually and jointly, had a significant association with neutropenia toxicity.
|
20028759 |
2010 |
Leukopenia
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The CDA A-76C, dCK C-1205T, RRM1 A33G, and hENT1 C913T genotypes were significantly associated with grade 3 to 4 neutropenia (P = .020, .015, .003, and .017, respectively).The CDA A-76C and hENT1 A-201G genotypes were significantly associated with tumor response to therapy (P = .017 and P = .019).
|
20665488 |
2010 |
Leukopenia
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
In NSCLC patients, CDA+435 C>T variants were associated with response (p=0.026) and time to progression (p=0.016) and SLC28A1+1561 G>A variants were associated with neutropenia (p=0.030) and thrombocytopenia nadir (p=0.037).
|
18538445 |
2009 |
Leukopenia
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The CDA Lys(27)Lys polymorphism significantly correlated with better clinical benefit (P = 0.04) and grade > or =3 neutropenia and thrombocytopenia, as well as with longer TTP and OS (P = 0.006 and P = 0.002, respectively), whereas no significant associations were found among ERCC1 and XPD polymorphisms and both response and clinical outcome.
|
18347182 |
2008 |